ADMA Biologics Sees Unusually High Options Volume (NASDAQ:ADMA)

ADMA Biologics Inc (NASDAQ:ADMA) was the target of some unusual options trading on Friday. Investors bought 5,039 put options on the stock. This is an increase of approximately 72% compared to the average volume of 2,926 put options.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Westfield Capital Management Co. LP bought a new stake in shares of ADMA Biologics during the third quarter valued at approximately $74,866,000. Capital Research Global Investors acquired a new position in ADMA Biologics during the 3rd quarter worth $47,702,000. Caligan Partners LP bought a new position in ADMA Biologics in the 3rd quarter valued at $38,653,000. Vaughan Nelson Investment Management L.P. bought a new position in ADMA Biologics in the 2nd quarter valued at $32,786,000. Finally, Thrivent Financial for Lutherans increased its stake in shares of ADMA Biologics by 78.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after buying an additional 1,453,924 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Trading Down 0.7%

ADMA stock opened at $17.95 on Friday. The business has a fifty day moving average price of $18.04 and a 200 day moving average price of $17.13. ADMA Biologics has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 20.87 and a beta of 0.47. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.13 and a quick ratio of 3.65.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The company had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. During the same quarter in the previous year, the firm earned $0.15 earnings per share. The business’s revenue was up 12.0% on a year-over-year basis. Analysts expect that ADMA Biologics will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.